NCT02794792View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

PHASE3CompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

March 2, 2017

Study Completion Date

June 20, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Ipragliflozin L-proline

Oral

DRUG

Metformin

Oral

DRUG

Placebo

Oral

Trial Locations (14)

117036

Site RU70011, Moscow

119034

Site RU70005, Moscow

121374

Site RU70003, Moscow

125315

Site RU70009, Moscow

150003

Site RU70001, Yaroslavl

150062

Site RU70013, Yaroslavl

191119

Site RU70008, Saint Petersburg

194354

Site RU70014, Saint Petersburg

197022

Site RU70007, Saint Petersburg

197706

Site RU70002, Saint Petersburg

400001

Site RU70015, Volgograd

410012

Site RU70004, Saratov

443067

Site RU70006, Samara

603018

Site RU70010, Nizhny Novgorod

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02794792 - A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin | Biotech Hunter | Biotech Hunter